BioSpace News Archive

Biora Therapeutics, Inc today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.

Intelligent Bio Solutions Inc. today announced it has received guidance from the U.S. Food and Drug Administration (the “FDA”) regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge.

Carisma Therapeutics Inc. announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company’s lead product candidate, CT-0508.

Imagine a day when a urine test could inform a doctor precisely why a kidney transplant patient was experiencing organ rejection and suggest the best medication for specifically addressing the problem.

Abcam plc, a global leader in the supply of life science research tools, confirmed that it has received a letter of undertaking from Dr. Jonathan Milner withdrawing his notice dated May 30, 2023 which required the Company to call an Extraordinary General Meeting of its shareholders to consider certain resolutions proposed by him.

Intrinsic Therapeutics, Inc. today has announced the publication of results from a post-market study that the use of Barricaid in high-risk patients results in significantly fewer reherniations and reoperations when compared to patients treated with discectomy alone.

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology ( ICGEB ).

Shineco, Inc. announced that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd., signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd., to establish a joint venture company, Shangkang Life Science and Technology Co., Ltd.

Susan G. Komen ® , the world’s leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S.

Axsome Therapeutics, Inc. today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $75.00 per share.